Review Article

Oxidative Stress in Neurodegenerative Diseases: From a Mitochondrial Point of View

Giovanna Cenini1, Ana Lloret2, and Roberta Cascella3

1Institut für Biochemie und Molekularbiologie, University of Bonn, 53115 Bonn, Germany
2Department of Physiology, Faculty of Medicine, University of Valencia, Avda, Blasco Ibáñez, 17, 46010 Valencia, Spain
3Department of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, 50134 Florence, Italy

Correspondence should be addressed to Roberta Cascella; roberta.cascella@uniifi.it

Received 4 October 2018; Accepted 15 April 2019; Published 9 May 2019

Academic Editor: Anthony R. White

Copyright © 2019 Giovanna Cenini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Age is the main risk factor for a number of human diseases, including neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, which increasing numbers of elderly individuals suffer. These pathological conditions, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and spinocerebellar ataxia (SCA), are characterized by progressive loss of neuron cells, compromised motor or cognitive functions, and accumulation of abnormally aggregated proteins. Mitochondrial dysfunction is one of the main features of the aging process, particularly in organs requiring a high-energy source such as the heart, muscles, brain, or liver. Neurons rely almost exclusively on the mitochondria, which produce the energy required for most of the cellular processes, including synaptic plasticity and neurotransmitter synthesis. The brain is particularly vulnerable to oxidative stress and damage, because of its high oxygen consumption, low antioxidant defenses, and high content of polyunsaturated fats very prone to be oxidized. Thus, it is not surprising the importance of protecting systems, including antioxidant defenses, to maintain neuronal integrity and survival. Here, we review the role of mitochondrial oxidative stress in the aging process, with a specific focus on neurodegenerative diseases. Understanding the molecular mechanisms involving mitochondria and oxidative stress in the aging and neurodegeneration may help to identify new strategies for improving the health and extending lifespan.

1. Introduction

Aging is the primary risk factor for a number of human diseases, as well as neurodegenerative disorders [1], which increasing numbers of elderly individuals suffer. These pathological conditions, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and spinocerebellar ataxia (SCA), are characterized by progressive loss of neuron cells, compromised motor or cognitive functions, and accumulation of abnormally aggregated proteins [2, 3]. A growing body of evidence highlights bioenergetic impairments as well as alterations in the reduction-oxidation (redox) homeostasis in the brain with the increasing of the age. The brain is composed by highly differentiated cells that populate different anatomical regions and requires about 20% of body basal oxygen for its functions [4]. Thus, it is not surprising that alterations in brain energy metabolisms lead to neurodegeneration.

Cellular energy is mainly produced via oxidative phosphorylation taking place within mitochondria, which are crucial organelles for numerous cellular processes, such as energy metabolism, calcium homeostasis, lipid biosynthesis, and apoptosis [5, 6]. Glucose oxidation is the most relevant source of energy in the brain, because of its high rate of ATP generation needed to maintain neuronal energy demands [4]. Thus, neurons rely almost exclusively on the mitochondria, which produce the energy required for most of the cellular processes, including synaptic plasticity and neurotransmitter synthesis [7]. Furthermore, given the central role of mitochondria in energy metabolism and in the regulation of the redox homeostasis, the study of age-related mitochondrial disorders is becoming nowadays of growing interest. Here, we review the role of mitochondria...
in the aging process, with a specific focus on mitochondrial oxidative stress in neurodegenerative diseases.

2. What Is the Oxidative Stress?

Reactive oxygen species (ROS) are normally produced in the cell of living organisms as a result of normal cellular metabolism and are fundamental in the maintenance of cellular homeostasis. In physiological conditions, low to moderate concentrations of ROS are involved in processes such as immune response, inflammation, synaptic plasticity, learning, and memory [8]. However, the excess of ROS production can be harmful, producing adverse oxidative modifications to cell components including mitochondrial structures as the first targets of ROS-induced damage [9]. Nevertheless, the human body is equipped with a variety of antioxidants that serve to counterbalance the excessive production of oxidants and keep the homeostasis. However during the aging, the oxidant levels increase, while the antioxidant efficiency decreases generating an imbalance that leads to a noxious condition called oxidative stress and consequently to an oxidative damage of the main biomolecules such as proteins, lipids, nucleic acids, and carbohydrates. The overall picture intensifies in neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis.

Figure 1: Schematic representation of oxidative stress in health, aging, and neurodegenerative diseases. In healthy conditions, the oxidant levels mainly produced in mitochondria are kept under control due to efficient mechanisms of defense that counterbalance the excessive production of oxidants and keep the homeostasis. However during the aging, the oxidant levels increase, while the antioxidant efficiency decreases generating an imbalance that leads to a noxious condition called oxidative stress and consequently to an oxidative damage of the main biomolecules such as proteins, lipids, nucleic acids, and carbohydrates. The overall picture intensifies in neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis.
the oxidized bases, and they can be used as markers of RNA and DNA oxidation [22]. The involvement of nucleic acid oxidation in neurodegenerative diseases might cause not only the reduction of protein level but also translation errors in vivo with alteration of protein structure and function [23].

In the course of the evolution, the organisms have developed several mechanisms of protection against the noxious effects of ROS and RNS in such a way that the whole amount of prooxidants is under control, and the negative consequences are limited. The antioxidant molecules are divided into two groups: enzymatic and nonenzymatic compounds. The enzymatic group includes superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione reductase (GR). SOD is one of the first protective mechanisms against ROS and catalyzes the conversion of $\text{O}_2^-$ to $\text{H}_2\text{O}_2$ and $\text{O}_2$ [24]. The generated $\text{H}_2\text{O}_2$ is converted to water and $\text{O}_2$ by CAT. The nonenzymatic group involves glutathione (GSH), the most abundant antioxidant in most of the brain cells, thioredoxin (Trx), vitamins A, E, and C, and selenium. GSH reacts with ROS generating glutathione disulfide (GSSG) and enters a cycle together with GPx and GR. Vitamin E (also called $\alpha$-tocopherol) is a lipophilic molecule acting against the lipid peroxidation [25]. Vitamin C (also called ascorbic acid) is one of the most important watersoluble antioxidants. Selenium is a crucial cofactor for the enzymes GPx and thioredoxin reductase (TrxR) and essential trace elements. All together they act and balance the levels of ROS and RNS to avoid the onset and the propagation of harmful effect in the nearby tissues.

3. Mitochondrial Damage in Aging

Aging is a degenerative physiological process induced by the accumulation of cellular lesions leading progressively to organ dysfunction and death. Although our knowledge of the aging process remains far from being complete, understanding the basis of human aging is one of the great biomedical goals. The best known and most long-standing hypothesis to explain aging is the “free radical theory of aging” proposed by Harman and coworkers [26], which postulates that aging and age-associated degenerative diseases are the result of free radical attacks on cells and tissues. This theory was later extended by Miquel and coworkers [27] who focused on mitochondria as the main source of ROS in aging cells. In this relevant work, the authors explained how mitochondrial disorganization might be an important aspect of the age-related changes of postmitotic cells such as neurons and muscle cells. This view was based on electron microscopic and biochemical studies on insects and mammals. Finally, they offered a hypothesis on intrinsic mitochondrial senescence and its possible relation to age-related changes in other cell organelles. The theory is known nowadays as “the mitochondrial theory of aging.” Since this early publication, experimental evidences of the implication of mitochondria in aging have increased.

In addition to the energy generation through oxidative phosphorylation, mitochondria play an essential role in cell metabolic homeostasis, signaling, differentiation, and senescence [28]. Mitochondrial dysfunction is one of the main features of the aging process [29] (Figure 2), particularly in organs requiring a high-energy source such as the heart, muscles, brain, or liver. Although a large amount of data support the role of mitochondrial ROS production in aging, it has also recently been demonstrated the involvement of the mitochondrial permeability transition in the mechanisms of aging [30]. Indeed, the mitochondrial membrane potential appeared originally lower in old animals, and cellular peroxide levels were higher in cells from old animals with respect
to the young ones [31]. The age-associated decrease in mitochondrial membrane potential correlated with reduced ATP synthesis in tissues of old animals [32] and also in human fibroblasts from elderly subjects [33]. The mitochondrial permeability transition is due to a nonspecific pore called the mitochondrial permeability transition pore (mPTP) occurring when mitochondria become overloaded with calcium. Indeed, it is well known that aging alters cytosolic calcium pick-up and the sensitivity of the mPTP to calcium enhanced under oxidative stress conditions [34].

Using isolated mitochondria, in the past few decades, many studies revealed that the activity of respiratory enzyme complexes in the electron chain transport gradually declines with age in the liver, skin fibroblasts, brain, and skeletal muscle of humans [32, 33, 35, 36] (Figure 2). Moreover, mitochondrial morphology changed with age. Electron microscopic studies showed that mitochondrial disorganization accumulates with age in a variety of cells and tissues [26]. Although mitochondria are very dynamic organelles and can remodel their structure through fusion and fission [37], abnormalities in the process have been related to senescence in mammalian cells [38].

Age-associated oxidative damage to mtDNA was shown to correlate with mitochondrial GSH oxidation in the liver, kidney, and brain of rats and mice [39]. mtDNA deletions were also found to correlate with the level of oxidized guanines in mtDNA [40]. Furthermore, mtDNA increasingly accumulated mutations with age in a variety of human tissues, which include point mutations [41], large-scale deletions [42], and also tandem duplications [43] (Figure 2). On the other hand, mitochondrial rRNAs were oxidized and degraded under oxidative stress conditions [44]. Oxidized proteins also accumulate progressively during aging, and an important consequence is the unfolding phenomenon that causes protein aggregation [45] (Figure 2). Many respiratory enzymes are known to be the targets of oxidation, such as complex I and ATPase [46] (Figure 2). Finally, lipid peroxidation is particularly important in the inner mitochondrial membrane due to the high content of cardiolipin [47]. In fact, oxidative stress was found to decrease cardiolipin levels more than other lipids and this decline appeared directly related to the decrease of cytochrome oxidase activity [47].

Interestingly, a switch from glycolysis to respiratory metabolism in yeast has been found to increase ROS production, activate the antioxidant response, and increase NADPH production, causing lifespan extension and hormesis response [48]. Mitochondrial dysfunction has also been related to another aging-related process, the telomere shortening [49]. PGC-1a/b are the principal regulators of mitochondrial biogenesis and function and establish the connection between telomere shortening and mitochondria malfunction [50]. When DNA is damaged, p53 levels increase and PGC1α/b are inhibited consequently leading to mitochondrial dysfunction [49, 50]. PGC-1α was also found to decrease its activity inducing loss of SIRT1 activity and mitochondrial dysfunction, particularly in the muscle [51]. Interestingly, the overexpression of PGC-1α can improve aging muscle and plays a significant role in longevity [52]. On the other hand, DNA damage can also activate AKT and mTORC1, resulting in PGC-1b-dependent mitochondrial biogenesis and ROS generation [53].

4. Mitochondrial Oxidative Stress and Its Role in Neurodegenerative Diseases

As already described above, mitochondria are key multifunctional organelles that play multiple important functions in the cell. They are essential not only in energy production but also in thermogenesis, calcium homeostasis, generating and maintaining key cellular metabolites, and redox signaling [5]. Neurons are postmitotic highly differentiated cells with a lifespan similar to that of the whole organism [54]. These excitable cells are more sensitive to the accumulation of oxidative damages compared to dividing cells and are more prone to accumulating defective mitochondria during aging [54, 55]. Thus, it is not surprising the importance of protecting systems, including antioxidant defenses, to maintain neuronal integrity and survival.

All the neurodegenerative disorders share several common features, such as the accumulation of abnormally aggregated proteins and the involvement of oxidative damage and mitochondrial dysfunction. Many of the genes associated with PD or ALS are linked to mitochondria. In addition, all aggregated misfolded proteins (β-amyloid, tau, and α-synuclein) are known to inhibit mitochondrial function and induce oxidative stress [56]. Therefore, the identification of common mechanisms underlying neurodegenerative diseases, including mitochondrial dysfunction, will increase our understanding of the essential requirements for neuronal survival that can inform future neuroprotective therapies.

5. Alzheimer’s Disease

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder affecting the aged population, which is characterized by progressive deterioration of behavior, cognition, and functionality [57]. Although the pathophysiology is extremely complex and heterogeneous, the main hallmarks of AD are the senile plaques composed by extracellular deposition of amyloid beta (Aβ) peptide and the presence of intracellular tau neurofibrillary tangles (NFT) [57]. The aberrant protein aggregation results in multifactorial neuronal dysfunction affecting synaptic signaling, mitochondrial function, neuroinflammation, and neuronal loss [58, 59]. In particular, Aβ plaques were found to deplete Ca2+ ions storage in the endoplasmic reticulum (ER), resulting in cytosolic Ca2+ overload, which causes a reduction in endogenous GSH levels and ROS accumulation [60]. ROS-induced oxidative stress is one of the main important factors in the pathogenesis of AD as ROS overproduction is thought to play a critical role in the accumulation and deposition of Aβ peptides in AD [61].

The relationship between mitochondria and AD pathology is not so direct compared to other neurodegenerative disorders, although the role of oxidative stress and mitochondrial dysfunction is shown in different AD models.
Thus, a reduction in complex IV activity has been demonstrated in mitochondria from the hippocampus and platelets of AD patients and in AD caryid cells [63, 64]. Aggregation of Aβ peptides leads to oxidative stress, mitochondrial dysfunction, and energy failure prior to the development of plaque pathology [65] and can reduce mitochondrial respiration in neurons and astrocytes via the inhibition of complexes I and IV, thus causing ROS production [66]. The important role of mitochondrial ROS has been also confirmed by the results obtained with the antioxidant MitoQ, which can prevent cognitive decline, Aβ peptide accumulation, microglia inflammation, and synaptic loss in a transgenic mouse model of AD [67] and can extend lifespan and improve health in a transgenic Caenorhabditis elegans model of AD [68]. In addition, the inhibition of oxidative stress as a result of a polyunsaturated fatty acid diet improved cognition and memory in mice [69], rats [70], and protected worms from the paralysis by extending their lifespan [71].

It has been reported that the H$_2$O$_2$ production from synaptic mitochondria was more than fivefold higher than that from nonsynaptic mitochondria [72]. This fact indicates that neurons are more susceptible to oxidative damage than glial cells. Furthermore, isolated mitochondria from neurons incubated with Aβ peptides caused a fivefold increase in the rate of H$_2$O$_2$ production [73]. Moreover, Aβ peptides increased the aggregation of mitochondria isolated from neurons and caused cytochrome C release from mitochondria, both proapoptotic signals [73]. Studies performed in AD patients showed reduced cytochrome oxidase activity in platelets of AD subjects when compared to controls [74], and this mitochondrial defect was also demonstrated in the brain of AD patients [75]. Mitochondria from platelets of AD patients have been found depolarized, smaller on average, and less able to buffer calcium, showing lower ATP levels and an increase of oxidative stress, stress signaling, and apoptosis, with respect to controls [7]. Subjects with mild cognitive impairment also revealed mitochondrial deficiencies [76]. Fisar et al. have recently shown that both insufficiency in substrates entering into the oxidative phosphorylation system and functional disturbances in the electron transport system complex are responsible for the decrease in respiration observed in intact platelets of AD patients [77]. A very early decrease in mitochondrial complex activity has also been found in the entorhinal cortex of AD patients, but not in the frontal cortex [78].

Recently, it has been suggested that an imbalance in nuclear and mitochondrial genome-encoded oxidative phosphorylation transcripts may drive a negative feedback loop reducing mitochondrial translation and compromising oxidative phosphorylation efficiency, leading to ROS production [79]. Indeed, a deficiency of the mitochondrial oxidative phosphorylation system can impact directly on mitochondrial function and result in several disease phenotypes [80].

It has recently been shown that cells from late-onset AD patients exhibited an impaired mitochondrial metabolic potential and an abnormal redox potential, associated with reduced nicotinamide adenine dinucleotide metabolism and altered citric acid cycle activity [81]. Moreover, AD fibroblasts presented a significant reduction in mitochondrial length, changes in the expression of proteins that control mitochondrial fusion, and dysfunction of mitochondrial bioenergetics [82]. Martin-Maestro et al. also showed that multiple genes that control mitochondrial homeostasis, including fission and fusion, are downregulated in Alzheimer’s patients. These defects lead to strong accumulation of aged mitochondria in AD fibroblasts [83]. Accordingly, the analysis from AD patients of genes involved in autophagy and mitophagy demonstrated a downregulation, indicating that the recycling mechanism of these aged mitochondria might be impaired [83].

AD pathogenesis has also been linked to voltage-dependent anion channel 1 (VDAC1) [84], which is expressed in the mitochondrial outer membrane and regulates the main metabolic and energetic functions of the cell, including Ca$^{2+}$ homeostasis, oxidative stress, and mitochondrial-mediated apoptosis. Indeed, VDAC1 levels were found to increase in the AD brains and its inhibition has been proposed as the target of a novel strategy for diminishing cell death [84].

Mitochondria are highly abundant in synapsis cause of their on-site energy provision and calcium modulation [85]. Via TOM import machinery [86] and/or by local production by γ-secretase [87], Aβ peptides accumulate inside the synaptic mitochondria [88]. Then, it probably interacts with the mitochondrial heme group [73] and/or with mitochondrial matrix proteins such as amyloid-binding alcohol dehydrogenase (ABAD) [188] and blocks the electronic transport thereby compromising ATP production [89] and synaptic function [64]. A recent study performed in isolated mammalian mitochondria showed that Aβ peptides impaired mitochondrial import of nuclear-encoded precursor proteins due to a coaggregation process [90].

It has been showed from different laboratories that oxidative and nitrosative stress markers were substantially increased in AD, encouraging the idea about the crucial role of these two pathways in the progression of the disease. In several postmortem cortex areas not only from sporadic and familiar AD patients but also from patients affected by mild cognitive impairment (MCI), the levels of protein carbonyls were substantially increased compared to age-matched control subjects [91, 92]. In addition, the levels of carbonyl reductase (CR) were also found to increase in the AD brains, suggesting that the brain tries to counteract protein oxidation [15]. About markers of nitrosative stress in AD, proteomic approaches have identified a large number of proteins which are nitrated in the MCI and AD brains [93, 94]. These proteins are involved in several cellular functions such as energy metabolism, structural maintenance, pH regulation, and antioxidant.

Lipid peroxidation seems to play a particular role not only in aging but also in the pathogenesis of AD [95] and its products could be used as markers for AD identification since early stages (MCI). Indeed, in CSF and the brains from AD and MCI subjects, it has been found elevated levels of lipid peroxidation products such as HNE, malondialdehyde (MDA), acrolein, F$_2$-isoprostanate, F$_4$-isoprostanate, and neuroprostane [96, 97], have been found elevated, while MDA
levels was also found high in plasma and serum from AD patients [98] and colocalized with neurofibrillary tangles and senile plaques [99]. The decrease of the detoxification system efficiency in MCI and AD caused the accumulation of HNE protein adducts in neuronal cells [100]. Also in the blood, a significant increase of HNE levels has been found in AD patients compared to healthy subjects [101]. Acrolein has been reported to react with DNA bases leading to the formation of acrolein-deoxyguanosine in the AD brain [102].

Several papers published in the early nineties suggested an important role of glycation in the formation of neurofibrillary tangles and senile plaques [103, 104]. Like many other markers of oxidative stress, AGEs were also found to increase in CSF of AD patients, as well as their receptor levels in microglia cells of the AD brains [104]. While the picture in the brain is clear, the results about AGEs and soluble RAGE levels obtained in the blood from AD patients are controversial [105].

A considerable amount of evidences supports the early involvement of nucleic acids and oxidation in the cascade of neurodegeneration. DNA and RNA damage is a feature of the AD brain as well as of peripheral tissue [106], mtDNA of cortical neurons in AD patients was found deleted with respect to age-matched controls [107]. Later, sporadic mutations in the mtDNA control regions in AD patients were also identified [108]. Interestingly, 8-OHdG levels in the mtDNA of the cerebral cortex and cerebellum from AD patients were threefold higher than in age-matched controls [109]. RNA oxidation was observed in the postmortem brains of early and latest stages of AD [110], a presymptomatic case with familial AD mutation [111], and Down syndrome with AD pathology [112], suggesting that mRNA is highly sensitive to oxidative damage. Fivefold increase in oxidized RNA was also observed in CSF of AD cases [113]. All this data suggests that nucleic acid oxidation may be considered an early event in the progression of AD.

The antioxidant levels in AD were found to change not only in the brain but also in peripheral tissues. Most of the studies have found an overall decrease in antioxidant amount and activity in the blood of AD patients since the early phases, suggesting that the physiological equilibrium between ROS/RNS production and antioxidant is altered and consequently the amount of antioxidant available is strongly compromised. In particular, SOD levels, but not the activity [114], were found to be elevated in the hippocampus and amygdala of AD patients [115], while a decrease in SOD, GPx, and CAT levels was found in the frontal and temporal cortex [116]. Nevertheless, CAT activity was found to increase in AD erythrocytes [117], suggesting an independence of the redox status between the periphery and the brain.

GSH was also found to decrease in the MCI and AD brain and erythrocytes [114, 118]. Another recent study showed higher GSH levels in the anterior and posterior cingulated from MCI patients [119]. In addition to GSH, the enzymes involved in its metabolism were also analyzed. In particular, glutathione-S-transferase (GST), a sensitive target of oxidative and nitrosative stress, was found to be carbonylated in *C. elegans* expressing Aβ42 [120] and in canine model of aging [121]. GST was also found to be nitrated in inferior parietal lobe (IPL) from MCI patients [122] and significantly elevated in the AD hippocampus, causing a decrease of its activity [118]. Since GSTs catalyze the conjugation of HNE to glutathione (GSH), the decline of its activity consequently leads to the compromise of detoxification process of HNE [123] and an accumulation of HNE-modified proteins. All these studies suggest that an alteration of GSH metabolism at the early stages of the disease could be an early marker for the detection of AD.

Another family of antioxidants particularly affected by oxidative and nitrosative stress is peroxiredoxins (Prxs), which reduces H$_2$O$_2$ [124] and presents a redox-regulated chaperone activity [125]. Prx2 oxidation was found Aβ42 dependent in SAMP8 mice [126]. However, Prx2 expression was found to increase in the AD brains [127] and Prx6 is oxidatively modified in the MCI brains [122], suggesting the presence of a compensatory mechanism.

Vitamins E and C were also found to decrease in plasma from MCI and mild AD and in CSF from AD patients [128–130]. In line with these results, another study showed a positive correlation between plasma vitamin E levels and the risk to develop AD in an advanced age [131].

Selenium levels were also affected in AD plasma with an association to the cognitive decline [132]. Nevertheless, the plasma levels of selenium seem to be independent from those of the brain [133]. The levels of seleno-containing enzyme Trx1 were also found to increase in the AD brains [134], in particular in glial cells, but not in neurons [135]. On the contrary, the long cleavage product of Trx1, Trx80, was drastically reduced in the brains and CSF from AD and MCI patients and it could be used to distinguish the stable MCI from the MCI that evolve later to AD [136].

6. Parkinson’s Disease

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, after AD, which is characterized by the progressive degeneration of the dopaminergic neurons located in the substantia nigra (SN) pars compacta [137]. The main neuropathological hallmark of PD is the presence of intracellular inclusions known as Lewy bodies (LBs) and neurites (LNs) [138], predominantly composed by misfolded and aggregated forms of the presynaptic protein α-synuclein [139].

The implication of mitochondrial dysfunction in the pathology of PD has been shown for a long time [140, 141]. The aging-related mitochondrial decline and the increasing mtDNA damage/mutations are also been associated with the increased risk for PD [142]. Indeed, it has been reported that mtDNA can impair the capacity of the organelle quality control mechanisms and thereby amplify the initial insult through a progressively increase of metabolic dysfunction and oxidative stress [143]. In particular, in some models of PD, it has been shown that environmental xenobiotics were extremely toxic and caused mitochondrial dysfunction in dopaminergic neurons leading to parkinsonian phenotypes [144].
Furthermore, the protein α-synuclein associated with PD pathogenesis is known to target the mitochondria and to decrease their function [140–142, 145, 146]. Notably, a decline of complex I activity and elevated intracellular ROS have been reported in the SN of the postmortem brain of PD patients [140, 147]. The implication of the mitochondria in PD is also supported by the presence of PD-related genes such as PINK1, PARK2 (Parkin), DJ-1, and LRRK2 which regulate mitochondrial and ROS homeostasis [148–151]. PINK1 deficiency results in impaired respiration with inhibition of complex I, and mutations in PINK1 gene cause a recessive form of PD [152, 153]. Abnormal ROS production in the mitochondria of PINK1 knockout neurons has been found to inhibit the mitochondrial Na$^{+}$/Ca$^{2+}$ exchanger or glucose transporter and to be prevented by antioxidants [152, 154]. Mitochondrial ROS play an important role not only in the pathology of PINK1 (mutation or deficiency) but also in the physiology of PINK1/Parkin-related mitophagy, by the induction of mitochondrial recruitment of Parkin [155]. In addition, it has recently been reported that mitochondrial ROS production in familial and sporadic forms of PD caused DNA damage and activated the PARP enzyme-associated DNA repair mechanism [156].

Although monomeric α-synuclein is a physiological regulator of synaptic transduction and mitochondrial bioenergetics [157], the oligomeric species appeared toxic for cells [62, 158], inhibited mitochondrial complex I [159], and induced mitochondrial depolarization [160]. In addition, oligomeric α-synuclein caused ROS production [158] independently of the known enzymatic pathways that affected mitochondrial function and induced lipid peroxidation [161]. The role of α-synuclein in mitophagy, mitochondrial fission/fusion, and protein trafficking to this organelle has also been shown [162]. Neurodegenerative impairments were also found in α-synuclein transgenic mice through the activation of mPTP [163]. The opening of mPTP appeared to be induced by oligomeric α-synuclein with respect to the monomeric protein, due to their ability to induce calcium signal in a structure-specific manner [164] and to produce ROS in the presence of free metal ions [165].

In addition to the mitochondrial dysfunction and ROS production, PD is characterized by an overall increase of end-product markers of oxidative and nitrosative stress that reflects an extensive damage on the biomolecules. This strongly suggests that these three processes are interconnected and create a cascade of events promoting a neurodegenerative condition like PD. The SN from the postmortem brains showed increased protein carbonyl levels at high molecular weight compared to the control brains or other brain regions [165]. The levels of protein nitration were also found to increase in the PD brains [166]. A recent study showed increased α-synuclein nitration levels in the brain from individuals with synucleinopathy, suggesting a direct link between nitrosative damage and the progression of neurodegenerative synucleinopathies [167]. Interestingly, an in vitro study showed the nitration of mitochondrial complex I that might trigger overtime a cascade of deleterious events enhancing the overall oxidative damage in PD [168]. The postmortem brains of PD patients showed increased levels of lipid peroxidation markers and oxidized proteins [169]. In particular, HNE adducts were identified in dopaminergic cells of SN, CSF, and plasma from PD patients [170, 171] and significant differences were found in plasma of PD subjects treated with L-dopa therapy [171]. Moreover, MDA levels were found to be high and attached to α-synuclein in the SN and frontal cortex of PD cases [172] supporting the idea that lipid peroxidation might precede and contribute to α-synuclein aggregation. In PD plasma, MDA levels were also found to be increased and inversely related to the age of patients [173]. Glycation also showed a strong immunoreactivity in the SN and locus coeruleus of PD patients [174], suggesting its involvement in the chemical cross-linking, proteolytic resistance, and aggregation process. Overall, the levels of glycated proteins were significantly higher in the cerebral cortex of PD patients compared to age-matched controls [175]. Since in PD the catabolic pathway activity of the most glycation agents is lower [176], the AGE concentration rises up leading to the death of dopaminergic neurons. About DNA and RNA oxidation, the levels of 8-OHdG and 8-OHG were also found to be increased in different brain regions, including SN, in serum and CPS [177, 178].

The antioxidant status of PD was found significantly modified compared to age-matched healthy subjects, as well as in AD. In particular, SOD levels, but not the activity, were found to increase in the SN and basal ganglia from PD patients [179]. In contrast, the levels of other antioxidant enzymes such as CAT, GPx, and GR did not change in PD patients [179]. In contrast, the levels of other antioxidant enzymes such as CAT, GPx, and GR did not change in PD patients [179]. In contrast, the levels of other antioxidant enzymes such as CAT, GPx, and GR did not change in PD patients [179]. In contrast, the levels of other antioxidant enzymes such as CAT, GPx, and GR did not change in PD patients [179]. In contrast, the levels of other antioxidant enzymes such as CAT, GPx, and GR did not change in PD patients [179]. In contrast, the levels of other antioxidant enzymes such as CAT, GPx, and GR did not change in PD patients [179]. In contrast, the levels of other antioxidant enzymes such as CAT, GPx, and GR did not change in PD patients [179]. In contrast, the levels of other antioxidant enzymes such as CAT, GPx, and GR did not change in PD patients [179].

Anyway, studies in the animal models of PD showed different outcomes compared to the human sample analysis with a degree of controversy [182, 183] probably due to the temporal length of the experimental observation time.

### 7. Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of motor neurons in the anterior horn of the spinal cord, leading to muscle weakness, wasting, and spasticity [184]. ALS is classified as either familial or sporadic depending on whether there is a clearly defined, inherited genetic element. The onset of sporadic (sALS) is unknown, and thus, the identification of causal genes and environmental factors remains elusive. Mutations in the first ALS gene superoxide dismutase 1 (SOD1) were found in 1993 to segregate in several sALS pedigrees [185] and subsequently in a small number of unrelated sALS cases [186]. Fifteen years later, TAR DNA binding protein 43 (TDP-43) is found to be an important constituent of protein aggregates frequently observed in postmortem material of ALS patients [187]. Although it is not yet clear how such aggregates trigger neurodegeneration in ALS, mutations in the TDP-43 gene were reported in 3% of sALS and 1-5% of patients with sALS, suggesting that TDP-43 aggregates have a
central role in triggering ALS [188, 189]. The number of ALS genes increases and it appears that the mutant proteins encoded are involved in a variety of critical processes, including mitochondria function.

The link of mitochondria to ALS has been defined by the mutations in SOD1 gene since they were found in 20% of the fALS [190]. SOD1 is an ubiquitous enzyme with several functions, including scavenger of excessive superoxide radical (O$_2^-$) into oxygen, modulation of cellular respiration, energy metabolism, and posttranslational modification [191]. Several SOD1 mutations were shown to affect the folding of the protein, and it is believed that the ensuing toxic gain of function might be caused by the accumulation of misfolded proteins inside the intermembrane space of mitochondria [192] with generation of free radicals that eventually lead to cell injury and death [193, 194]. Even if this may not be the main triggering mechanism, it is nonetheless recognized that mitochondrial dysfunction is central to SOD1 pathogenesis [195]. Although SOD dysfunction leads to a loss of antioxidant capability, evidences have shown that the silencing of SOD1 in mice does not lead to neurodegenerative conditions [196]. In contrast, it has recently been reported that mutant SOD1 can disturb the amino acid biosynthesis of cells in a yeast model and mediate cellular destruction, accounting for the neural degeneration in ALS [197]. In addition, the reduction of the mitochondrial ROS in neurons of a double UCP-SOD1 transgenic mouse model did not recover mitochondrial function and accelerated the progression of the disease [198]. The activity of SOD was also found to reduce in red blood cells from ALS patients [199], while SOD1 activity in the CSF showed conflicting results [200, 201].

Mitochondrial oxidative damage has also been demonstrated in patients affected by sALS [202] and in a transgenic mouse model expressing a fALS-linked mutant Cu/Zn SOD1 [203]. The spinal cord and motor cortex showed increased levels of protein carbonyls, nitrosoative stress, and NOS [204, 205] suggesting selectivity about protein oxidation and nitration in ALS. Mutations of other genes associated with ALS, such as TDP-43, FUS/TLS, and p62, were also found to increase mitochondrial ROS and oxidative stress [206, 207]. In addition, exogenous-added TDP-43 aggregates were found to accumulate in the cytosol of neuronal cells causing intracellular ROS production [208].

Modifications in HNE-bound proteins have been detected in ventral horn motor neurons [209], and high free HNE levels were found high in CSF and serum of ALS patients [210, 211] suggesting a diffusion of HNE from the brain to the periphery. Proteomic analysis on the spinal cord of an ALS mouse model and in CSF [212] revealed an increase in lipid peroxidation, which was also found to increase the levels of MDA-protein adducts in the lumbar spinal and cervical cord before the onset of clinical motor signs in a murine model of ALS [213]. Despite acrolein-protein adducts were not detectable in the spinal cord of ALS patients, free MDA detection has been also confirmed in ALS subjects [205].

Glycation was first detected in the spinal cord and brain samples of both sALS and fALS [214, 215] as well as in SOD1 transgenic mice. Surprisingly, the levels of soluble RAGE were found lower in serum of ALS patients with respect to control subjects [216]. From a mechanistical point of view, in vitro glycation affected negatively the structure and the activity of SOD1 [217]. The roles of mRNA and DNA oxidation were showed for the first time in a mouse model of ALS, suggesting the presence of an early event before the degeneration of the motor neurons and appearance of all the symptoms. ALS patients presented an increase of nuclear 8-OHdG in the motor cortex and 10-fold higher in the spinal cord tissue [205], as well as in plasma, urine, and CSF, compared to healthy people [218].

In addition to SOD1, other antioxidants showed changes in level and activity in peripheral tissues or CSF. Anyway, the modification of GSH, GPx, and GR activities appears fluctuating in the analyzed samples, suggesting a grade of variability [219], together with the variability of the pathogenic mechanisms that both lead to a fluctuation in the antioxidant profiles of ALS patients [220]. In some studies, the levels and the activities of these enzymes were found to decrease in erythrocytes [221] and in the motor cortex [222] from ALS patients. However, in another study, the GSSG/GSH ratio was found to decrease [223], and the GPx level and the GR activity were enhanced in erythrocytes, serum, and CSF [201, 224, 225]. Moreover, other studies showed that GR activity in red blood cells from ALS patients did not change, whereas CAT levels and activity were diminished [201, 224]. In addition, plasma levels of nonenzymatic antioxidants were inconsistent, with some studies showing elevated levels [226] and other with no change [227] proving again the grade of variability of the disease.

8. Mitochondrial Dynamics and Neurodegeneration

Mitochondria are organelles with high mobility inside the cells. They can change size, morphology, and position and can also suffer fission and fusion. Fission is the process to obtain two or more daughter mitochondria from the division of a single. Fusion is the opposite: the union of two or more mitochondria to form a unique structure [228] (Figure 3). Fission and fusion are normal processes that occur continuously in many cell types. Fission is facilitated by Drp1, a protein with GTPase activity which in the mitochondrial outer membrane forms chains promoting the mitochondrial division. The chain is stabilized by MfD49 and MfD51 proteins that previously form a complex with Mff and Fis1 (Figure 3). Fusion is mediated by OPA-1 which controls the mitochondrial inner membrane fusion and by Mfn1 and Mfn2 which control the mitochondrial outer membrane fusion [229] (Figure 3).

Mitochondrial dynamics were found to be impaired in neurodegeneration. In particular, the AD brains showed abnormal expression of mitochondrial fusion and fission proteins [230], but the results are controversial. Indeed, Wang et al. reported that levels of Opal1, Drp1, Mfn1, and Mfn2 are significantly decreased, whereas the levels of Fis1 increased in the hippocampus of AD patients [231]. However, another study found increased levels of Fis1 and Drp1 and decreased levels of Mfn1, Mfn2, and Opal1 in the AD
frontal cortex [232]. Moreover, the knock-in mouse Drp1+/- crossed with a mouse model of AD exhibited improved mitochondrial function [233].

Mitochondrial fission and fusion were also found to be altered in PD patients, with increased levels of p-Drp1 in white cells [234]. Moreover, α-synuclein induced the inhibition of mitochondrial fusion [235] by interacting with outer membrane lipids. Experiments performed in Drosophila showed that Parkin and PINK1 regulate mitochondrial dynamics in a Drp1-depending manner [236]. Both proteins are implicated in mitophagy [237] and also in mitochondrial distribution in axons [238]. DJ-1, another important PD-related protein, also regulates mitochondrial fission as consequence of a race in ROS production and its effects can be reversed by over-expression of Parkin and PINK1 [239]. Moreover, LRRK2 was also found to change Drp1 leading to mitochondrial fragmentation [240].

Lastly, mitochondrial dynamics were also altered in ALS. Indeed, an increase in mitochondrial fission is due to excessive Drp1 levels in the ALS models [241]. Moreover, changes in the levels of Fis1, Mfn1, OPA1, and Drp1 preceded motor-neuron loss and symptom onset in SOD1 mutant [242]. Mitochondrial fragmentation was also found to increase both in mutant TDP-43 and FUS, and the expression of mitochondrial fission and fusion regulators appeared modified [243, 244]. Moreover, the inactivation of Drp1 or Mfn2 prevented the deficits in mitochondrial trafficking in motoneurons of mutant SOD1 or TDP-43 [243, 245].

Taking into account that mitochondrial fission and fusion proteins regulate the assembly of respiratory complexes, the direct involvement of mitochondrial fission and fusion dynamics in mitochondrial bioenergetics could be central [246]. Therefore, it is reasonable to point out that altered mitochondrial fission and fusion is probably a mechanism leading to mitochondrial dysfunction in neurodegeneration.

9. Conclusion

Neurodegenerative diseases are becoming increasingly prevalent in our aged populations, thus representing a primary health problem especially for this age group [4, 247]. Tremendous efforts have been already made to identify neuropathological, biochemical, and genetic biomarkers of the diseases for a diagnosis at earlier stages.

In the past thirty years, an extensive research has been performed to understand the role of mitochondria and oxidative stress not only in physiological aging, but also in neurodegenerative diseases. The whole outcome clearly affirms that both processes get impaired during aging and are established features significantly involved in the progress, if not the onset, of neurodegenerative disorders. In this moment, it is still not clear if mitochondrial dysfunction and oxidative stress could be used as markers for an early detection of aging dysfunctions or be a valid therapeutic target. However, a better knowledge of the mechanism involving mitochondria and oxidative stress in the aging process and neurodegeneration may elicit new strategies for improving the quality of life of
the elderly and it would have a positive impact on the entire modern society.

**Conflicts of Interest**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Authors’ Contributions**

Giovanna Cenini and Ana Lloret have contributed equally to the manuscript.

**References**

[1] T. Niccoli and L. Partridge, "Ageing as a risk factor for disease," *Current Biology*, vol. 22, no. 17, pp. R741–R752, 2012.

[2] Alzheimer's Association, "2016 Alzheimer's disease facts and figures," *Alzheimer's & Dementia*, vol. 12, no. 4, pp. 459–509, 2016.

[3] P. Ibáñez, A. M. Bonnet, B. Dé barges et al., "Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease," *The Lancet*, vol. 364, no. 9440, pp. 1169–1171, 2004.

[4] P. Schöpfel and G. Reiser, "Why does brain metabolism not favor burning of fatty acids to provide energy? - Reflections on disadvantages of the use of free fatty acids as fuel for brain," *Journal of Cerebral Blood Flow & Metabolism*, vol. 33, no. 10, pp. 1493–1499, 2013.

[5] E. F. Smith, P. J. Shaw, and K. J. de Vos, "The role of mitochondria in amyotrophic lateral sclerosis," *Neuroscience Letters*, 2017.

[6] B. G. Hill, G. A. Benavides, J. R. Lancaster et al., "Integration of cellular bioenergetics with mitochondrial quality control and autophagy," *Biological Chemistry*, vol. 393, no. 12, pp. 1485–1512, 2012.

[7] M. P. Mattson, M. Gleichmann, and A. Cheng, "Mitochondria in neuroplasticity and neurological disorders," *Neuron*, vol. 60, no. 5, pp. 748–766, 2008.

[8] K. T. Kishida and E. Klann, "Sources and targets of reactive oxygen species in synaptic plasticity and memory," *Antioxidants & Redox Signaling*, vol. 9, no. 2, pp. 233–244, 2007.

[9] A. C. Rego and C. R. Oliveira, "Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases," *Neurochemical Research*, vol. 28, no. 10, pp. 1563–1574, 2003.

[10] H. P. Indo, H. C. Yen, I. Nakanishi et al., "A mitochondrial superoxide theory for oxidative stress diseases and aging," *Journal of Clinical Biochemistry and Nutrition*, vol. 56, no. 1, pp. 1–7, 2015.

[11] A. Grimm, K. Friedland, and A. Eckert, "Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer’s disease," *Biogerontology*, vol. 17, no. 2, pp. 281–296, 2016.

[12] J. N. Cobley, M. L. Fiorello, and D. M. Bailey, "13 reasons why the brain is susceptible to oxidative stress," *Redox Biology*, vol. 15, pp. 490–503, 2018.

[13] R. T. Dean, S. Fu, R. Stocker, and M. J. Davies, "Biochemistry and pathology of radical-mediated protein oxidation," *Biochemical Journal*, vol. 324, no. 1, pp. 1–18, 1997.

[14] D. A. Butterfield and E. R. Stadtman, "Chapter 7 Protein oxidation processes in aging brain," *Advances in Cell Aging and Gerontology*, vol. 2, pp. 161–191, 1997.

[15] B. Balcz, L. Kirchner, N. Cairns, M. Fountoulakis, and G. Lubec, "Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer’s disease," in *Protein Expression in Down Syndrome Brain*, G. Lubec, Ed., vol. 61, pp. 193–201, Springer, Vienna, 2001.

[16] S. Bartesaghi and R. Radi, "Fundamentals on the biochemistry of peroxynitrite and protein tyrosine nitration," *Redox Biology*, vol. 14, pp. 618–625, 2018.

[17] T. T. Reed, "Lipid peroxidation and neurodegenerative disease," *Free Radical Biology and Medicine*, vol. 51, no. 7, pp. 1302–1319, 2011.

[18] A. Winczura, D. Zdralik, and B. Tudek, "Damage of DNA and proteins by major lipid peroxidation products in genome stability," *Free Radical Research*, vol. 46, no. 4, pp. 442–459, 2012.

[19] G. Vistoli, D. de Maddis, A. Cipak, N. Zarkovic, M. Carini, and G. Aldini, "Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation," *Free Radical Research*, vol. 47, Supplement 1, pp. 3–27, 2013.

[20] N. Ahmed, "Advanced glycation endproducts—role in pathology of diabetic complications," *Diabetes Research and Clinical Practice*, vol. 67, no. 1, pp. 3–21, 2005.

[21] M. S. Cooke, M. D. Evans, M. Dizdaroglu, and J. Lunec, "Oxidative DNA damage: mechanisms, mutation, and disease," *The FASEB Journal*, vol. 17, no. 10, pp. 1195–1214, 2003.

[22] H. J. Helbock, K. B. Beckman, and B. N. Ames, "8-Hydroxydeoxyguanosine and 8-hydroxyguanine as biomarkers of oxidative DNA damage," *Methods in Enzymology*, vol. 300, pp. 156–166, 1999.

[23] S. Dukan, A. Farewell, M. Ballesteros, F. Taddei, M. Radman, and T. Nystrom, "Protein oxidation in response to increased transcriptional or translational errors," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 11, pp. 5746–5749, 2000.

[24] H. Rodriguez-Rocha, A. Garcia-Garcia, C. Pickett et al., "Compartmentalized oxidative stress in dopaminergic cell death induced by pesticides and complex I inhibitors: distinct roles of superoxide anion and superoxide dismutases," *Free Radical Biology and Medicine*, vol. 61, pp. 370–383, 2013.

[25] R. Brigelius-Flohé and M. G. Traber, "Vitamin E: function and metabolism," *The FASEB Journal*, vol. 13, no. 10, pp. 1145–1155, 1999.

[26] D. Harman, "Aging: a theory based on free radical and radiation chemistry," *Journal of Gerontology*, vol. 11, no. 3, pp. 298–300, 1956.

[27] J. Miquel, A. C. Economos, J. Fleming, and J. E. Johnson Jr, "Mitochondrial role in cell aging," *Experimental Gerontology*, vol. 15, no. 6, pp. 575–591, 1980.

[28] T. E. S. Kauppila, J. H. K. Kauppila, and N. G. Larsson, "Mammalian mitochondria and aging: an update," *Cell Metabolism*, vol. 25, no. 1, pp. 57–71, 2017.

[29] C. López-Otín, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, "The hallmarks of aging," *Cell*, vol. 153, no. 6, pp. 1194–1217, 2013.
[30] B. A. I. Payne and P. F. Chinnery, “Mitochondrial dysfunction in aging: much progress but many unresolved questions,” *Biochimica et Biophysica Acta (BBA) - Bioenergetics*, vol. 1847, no. 11, pp. 1347–1353, 2015.

[31] J. Sastre, F. V. Pallardó, R. Plá et al., “Aging of the liver: age-associated mitochondrial damage in intact hepatocytes,” *Hepatology*, vol. 24, no. 5, pp. 1199–1205, 1996.

[32] T. M. Hagen, D. L. Yowe, J. C. Bartholomew et al., “Mitochondrial decay in hepatocytes from old rats: membrane potential declines, heterogeneity and oxidants increase,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 7, pp. 3064–3069, 1997.

[33] M. Greco, G. Villani, F. Mazzucchelli, N. Bresolin, S. Papa, and G. Attardi, “Marked-aging-related decline in efficiency of oxidative phosphorylation in human skin fibroblasts,” *The FASEB Journal*, vol. 17, no. 12, pp. 1706–1708, 2003.

[34] A. P. Halestrap and A. P. Richardson, “The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury,” *Journal of Molecular and Cellular Cardiology*, vol. 78, pp. 129–141, 2015.

[35] J. Ojaimi, C. L. Masters, K. Opeskin, P. McKelvie, and E. Byrne, “Mitochondrial respiratory chain activity in the human brain as a function of age,” *Mechanisms of Ageing and Development*, vol. 111, no. 1, pp. 39–47, 1999.

[36] I. Trounce, E. Byrne, and S. Marzuki, “Decline in skeletal muscle mitochondrial respiratory chain function: possible factor in ageing,” *The Lancet*, vol. 333, no. 8639, pp. 637–4639, 1989.

[37] H. Chen and D. C. Chan, “Mitochondrial dynamics—fusion, fission, movement, and mitophagy—in neurodegenerative diseases,” *Human Molecular Genetics*, vol. 18, no. R2, pp. R169–R176, 2009.

[38] S. Lee, S. Y. Jeong, W. C. Lim et al., “Mitochondrial fission and fusion mediators, hFis1 and OPA1, modulate cellular senescence,” *Journal of Biological Chemistry*, vol. 282, no. 31, pp. 22977–22983, 2007.

[39] J. G. de la Asuncion, A. Millan, R. Pla et al., “Mitochondrial glutathione oxidation correlates with age-associated oxidative damage to mitochondrial DNA,” *The FASEB Journal*, vol. 10, no. 2, pp. 333–338, 1996.

[40] M. Hayakawa, K. Hattori, S. Sugiyama, and T. Ozawa, “Age-associated oxygen damage and mutations in mitochondrial DNA in human hearts,” *Biochemical and Biophysical Research Communications*, vol. 189, no. 2, pp. 979–985, 1992.

[41] Y. Michikawa, F. Mazzucchelli, N. Bresolin, G. Scarlato, and G. Attardi, “Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication,” *Science*, vol. 286, no. 5440, pp. 774–779, 1999.

[42] H. C. Lee, C. Y. Pang, H. S. Hsu, and Y. H. Wei, “Differential accumulations of 4,977 bp deletion in mitochondrial DNA of various tissues in human aging,” *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, vol. 1226, no. 1, pp. 37–43, 1994.

[43] Y. H. Wei, C. Y. Pang, B. J. You, and H. C. Lee, “Tandem duplications and large-scale deletions of mitochondrial DNA are early molecular events of human aging process,” *Annals of the New York Academy of Sciences*, vol. 786, no. 1, pp. 82–101, 1996.

[44] D. R. Crawford, Y. Wang, G. P. Schools, J. Kochheiser, and K. J. A. Davies, “Down-regulation of mammalian mitochondrial RNAs during oxidative stress,” *Free Radical Biology and Medicine*, vol. 22, no. 3, pp. 551–559, 1997.

[45] S. Reeg and T. Grune, “Protein oxidation in aging: does it play a role in aging progression?,” *Antioxidants & Redox Signaling*, vol. 23, no. 3, pp. 239–255, 2015.

[46] G. Lippe, M. Comelli, D. Mazzilis, F. D. Sala, and I. Mavelli, “The inactivation of mitochondrial F1 ATPase by H2O2 is mediated by iron ions not tightly bound in the protein,” *Biochemical and Biophysical Research Communications*, vol. 181, no. 2, pp. 764–770, 1991.

[47] G. Paradis, F. M. Ruggiero, G. Petrosillo, and E. Quagliariello, “Age-dependent decline in the cytochrome c oxidase activity in rat heart mitochondria: role of cardioli- pin,” *FEBS Letters*, vol. 406, no. 1-2, pp. 136–138, 1997.

[48] M. Musa, M. Periç, P. Bou Dib et al., “Heat-induced longevity in budding yeast requires respiratory metabolism and glutathione recycling,” *Aging*, vol. 10, no. 9, pp. 2407–2427, 2018.

[49] E. Sahin, S. Colla, M. Liesa et al., “Telomere dysfunction induces metabolic and mitochondrial compromise,” *Nature*, vol. 470, no. 7334, pp. 359–365, 2011.

[50] A. Dabrowska, J. L. Venero, R. Iwasawa et al., “PGC-1α controls mitochondrial biogenesis and dynamics in lead-induced neurotoxicity,” *Aging*, vol. 7, no. 9, pp. 629–643, 2015.

[51] E. F. Fang, M. Scheibe-Knudsen, L. E. Brace et al., “Defective mitophagy in XPA via PARP-1 hyperactivation and NAD+/SIRT1 reduction,” *Cell*, vol. 157, no. 4, pp. 882–896, 2014.

[52] S. Garcia, N. Nissanka, E. A. Maroco et al., “Overexpression of PGC-1α in aging muscle enhances a subset of young-like molecular patterns,” *Aging Cell*, vol. 17, no. 2, article e12707, 2018.

[53] C. Correia-Melo, F. D. M. Marques, R. Anderson et al., “Mitochondria are required for pro-aging features of the senescent phenotype,” *The EMBO Journal*, vol. 35, no. 7, pp. 724–742, 2016.

[54] A. Terman, T. Kurz, M. Navratil, E. A. Arriaga, and U. T. Brunk, “Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial–lysosomal axis theory of aging,” *Antioxidants & Redox Signaling*, vol. 12, no. 4, pp. 503–535, 2010.

[55] A. Kowald and T. B. L. Kirkwood, “Accumulation of defective mitochondria through delayed degradation of damaged organelles and its possible role in the aging of post-mitotic and dividing cells,” *Journal of Theoretical Biology*, vol. 202, no. 2, pp. 145–160, 2000.

[56] A. Y. Abramov, A. V. Berezhnov, E. I. Fedotova, V. P. Zinchenko, and L. P. Dolgacheva, “Interaction of misfolded proteins and mitochondria in neurodegenerative disorders,” *Biochemical Society Transactions*, vol. 45, no. 4, pp. 1025–1033, 2017.

[57] H. W. Querfurth and F. M. LaFerla, “Alzheimer’s disease,” *New England Journal of Medicine*, vol. 362, no. 4, pp. 329–344, 2010.

[58] D. J. Selkoe and J. Hardy, “The amyloid hypothesis of Alzheimer’s disease at 25 years,” *EMBO Molecular Medicine*, vol. 8, no. 6, pp. 595–608, 2016.

[59] B. De Strooper and E. Karran, “The cellular phase of Alzheimer’s disease,” *Cell*, vol. 164, no. 4, pp. 603–615, 2016.

[60] E. Ferreiro, C. R. Oliveira, and C. M. F. Pereira, “The release of calcium from the endoplasmic reticulum induced by amyloid-beta and prion peptides activates the mitochondrial...
apoptotic pathway,” Neurobiology of Disease, vol. 30, no. 3, pp. 331–342, 2008.

[61] D. J. Bonda, X. Wang, G. Perry et al., “Oxidative stress in Alzheimer disease: a possibility for prevention,” Neuropharmacology, vol. 59, no. 4-5, pp. 290–294, 2010.

[62] P. R. Angelova and A. Y. Abramov, “Alpha-synuclein and beta-amyloid – different targets, same players: calcium, free radicals and mitochondria in the mechanism of neurodegeneration,” Biochemical and Biophysical Research Communications, vol. 483, no. 4, pp. 1110–1115, 2017.

[63] J. P. Sheehan, R. H. Swerdlow, S. W. Miller et al., “Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer’s disease,” The Journal of Neuroscience, vol. 17, no. 12, pp. 4612–4622, 1997.

[64] H. Du, L. Guo, S. Yan, A. A. Sosunov, G. M. McKhann, and S. ShiDu Yan, “Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 43, pp. 18670–18675, 2010.

[65] C. Caspersen, N. Wang, J. Yao et al., “Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease,” The FASEB Journal, vol. 19, no. 14, pp. 2040–2041, 2005.

[66] C.S.Casley,L.Canevari,J.M.Land,J.B.Clark,andM.A.Sharpe,“β-amylloid inhibits integrated mitochondrial respiration and key enzyme activities,” Journal of Neurochemistry, vol. 80, no. 1, pp. 91–100, 2002.

[67] "The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease,” Journal of Neurochemistry, vol. 31, no. 44, pp. 15703–15715, 2011.

[68] L.F.Ng,J.Gruber,I.K.Cheahetal.,“Themitochondria-targeted antioxidant MitoQ extends lifespan and improves healthspan of a transgenic Caenorhabditis elegans model of Alzheimer disease,” Free Radical Biology and Medicine, vol. 71, pp. 390–401, 2014.

[69] A. Elharram, N. M. Czegledy, M. Golod et al., “Deuterium-reinforced polyunsaturated fatty acids improve cognition in a mouse model of sporadic Alzheimer’s disease,” The FEBS Journal, vol. 284, no. 23, pp. 4083–4095, 2017.

[70] M. Zampagni, D. Wright, R. Cascella et al., “Novel S-acetyl glutathione derivatives prevent amyloid oxidative stress and cholinergic dysfunction in Alzheimer disease models,” Free Radical Biology and Medicine, vol. 52, no. 8, pp. 1362–1371, 2012.

[71] R. Cascella, E. Evangelisti, M. Zampagni et al., “S-linolenoyl glutathione intake extends life-span and stress resilience via Sir-2.1 upregulation in Caenorhabditis elegans,” Free Radical Biology and Medicine, vol. 73, pp. 127–135, 2014.

[72] J. Viña, A. Lloret, S. L. Vallés et al., “Mitochondrial oxidant signalling in Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 11, no. 2, pp. 175–181, 2007.

[73] A. Lloret, M. C. Badia, N. J. Mora et al., “Gender and age-dependent differences in the mitochondrial apoptogenic pathway in Alzheimer’s disease,” Free Radical Biology and Medicine, vol. 44, no. 12, pp. 2019–2025, 2008.

[74] W. D. Parker Jr, C. M. Filley, and J. K. Parks, “Cytochrome oxidase deficiency in Alzheimer’s disease,” Neurology, vol. 40, no. 8, pp. 1302-1303, 1990.

[75] I. Maurer, S. Zierer, and H. J. Möller, “A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients,” Neurobiology of Aging, vol. 21, no. 3, pp. 455–462, 2000.

[76] D. F. Silva, J. E. Selfridge, J. Lu et al., “Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI hybrid cell lines,” Human Molecular Genetics, vol. 22, no. 19, pp. 3931–3946, 2013.

[77] Z. Fisar, J. Hroudová, H. Hansíková et al., “Mitochondrial respiration in the platelets of patients with Alzheimer’s disease,” Current Alzheimer Research, vol. 13, no. 8, pp. 930–941, 2016.

[78] M. Armand-Ugon, B. Ansoleaga, S. Berjaoui, and I. Ferrer, “Reduced mitochondrial activity is early and steady in the entorhinal cortex but it is mainly unmodified in the frontal cortex in Alzheimer’s disease,” Current Alzheimer Research, vol. 14, no. 12, pp. 1327–1334, 2017.

[79] K. Lunnun, A. Keohane, R. Pidsey et al., “Mitochondrial genes are altered in blood early in Alzheimer’s disease,” Neurobiology of Aging, vol. 53, pp. 36–47, 2017.

[80] I. Smetitik, L. van den Heuvel, and S. DiMauro, “The genetics and pathology of oxidative phosphorylation,” Nature Reviews Genetics, vol. 2, no. 5, pp. 342–352, 2001.

[81] K. C. Sonntag, W. J. Ryu, K. M. Amirault et al., “Late-onset Alzheimer’s disease is associated with inherent changes in bioenergetics profiles,” Scientific Reports, vol. 7, no. 1, article 14038, 2017.

[82] M. J. Pérez, D. P. Ponce, C. Osorio-Fuentealba, M. I. Behrens, and R. A. Quintanilla, “Mitochondrial bioenergetics is altered in fibroblasts from patients with sporadic Alzheimer’s disease,” Frontiers in Neuroscience, vol. 11, p. 553, 2017.

[83] P. Martin-Maestro, R. Gargini, E. García, G. Perry, J. Avila, and V. García-Escudero, “Slower dynamics and aged mitochondria in sporadic Alzheimer’s disease,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 9302761, 14 pages, 2017.

[84] V. Shoshan-Barmatz, E. Nahon-Crystal, A. Shteinfein-Kuzmin, and R. Gupta, “VDAC1, mitochondrial dysfunction, and Alzheimer’s disease,” Pharmacological Research, vol. 131, pp. 87–101, 2018.

[85] G. David and E. F. Barrett, “Mitochondrial Ca2+ uptake prevents desynchronization of quantal release and minimizes depletion during repetitive stimulation of mouse motor nerve terminals,” The Journal of Physiology, vol. 548, no. 2, pp. 425–438, 2003.

[86] C. A. Hansson Petersen, N. Alikhani, H. Behbahani et al., “The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 35, pp. 13145–13150, 2008.

[87] P. F. Pavlov, B. Wiehager, J. Sakai et al., “Mitochondrial γ-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein,” The FASEB Journal, vol. 25, no. 1, pp. 78–88, 2011.

[88] M. Manczak, T. S. Anekonda, E. Henson, B. S. Park, J. Quinn, and P. H. Reddy, “Mitochondria are a direct site of Aβ accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression,” Human Molecular Genetics, vol. 15, no. 9, pp. 1437–1449, 2006.
[89] C. Zhang, R. A. Rissman, and J. Feng, “Characterization of ATP alternations in an Alzheimer’s disease transgenic mouse model,” Journal of Alzheimer’s Disease, vol. 44, no. 2, pp. 375–378, 2015.

[90] G. Cenini, C. Rüb, M. Bruderek, and W. Voos, “Amyloid β-peptides interfere with mitochondrial preprotein import competence by a coaggregation process,” Molecular Biology of the Cell, vol. 27, no. 21, pp. 3257–3272, 2016.

[91] N. Bogdanovic, M. Zilmer, K. Zilmer, A. Rehema, and E. Karelson, “The Swedish APP670/671 Alzheimer’s disease mutation: the first evidence for strikingly increased oxidative injury in the temporal inferior cortex,” Dementia and Geriatric Cognitive Disorders, vol. 12, no. 6, pp. 364–370, 2001.

[92] R. Sultana, M. Perluigi, S. F. Newman et al., “Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer’s disease,” Antioxidants & Redox Signaling, vol. 12, no. 3, pp. 327–336, 2010.

[93] R. Sultana, H. F. Poon, J. Cai et al., “Identification of nitrated proteins in Alzheimer’s disease brain using a redox proteomics approach,” Neurobiology of Disease, vol. 22, no. 1, pp. 76–87, 2006.

[94] D. A. Butterfield, T. T. Reed, M. Perluigi et al., “Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer’s disease,” Brain Research, vol. 1148, pp. 243–248, 2007.

[95] D. A. Butterfield, M. L. Bader Lange, and R. Sultana, “Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer’s disease,” Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1801, no. 8, pp. 924–929, 2010.

[96] W. R. Markesbery, R. J. Kryscio, M. A. Lovell, and J. D. Morrow, “Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment,” Annals of Neurology, vol. 58, no. 5, pp. 730–735, 2005.

[97] T. J. Montine, J. Quinn, J. Kaye, and J. D. Morrow, “F2-isoprostanes as biomarkers of late-onset Alzheimer’s disease,” Journal of Molecular Neuroscience, vol. 33, no. 1, pp. 114–119, 2007.

[98] M. Padurariu, A. Ciobica, L. Hritcu, B. Stoica, W. Bild, and C. Stefanescu, “Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer’s disease,” Neuroscience Letters, vol. 469, no. 1, pp. 6–10, 2010.

[99] R. Dei, A. Takeda, H. Niwa et al., “Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer’s disease,” Acta Neuropathologica, vol. 104, no. 2, pp. 113–122, 2002.

[100] R. Sultana and D. A. Butterfield, “Oxidatively modified GST and MRPI in Alzheimer’s disease brain: implications for accumulation of reactive lipid peroxidation products,” Neurochemical Research, vol. 29, no. 12, pp. 2215–2220, 2004.

[101] M. L. Selley, D. R. Close, and S. E. Stern, “The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer’s disease,” Neurobiology of Aging, vol. 23, no. 3, pp. 383–388, 2002.

[102] X. Liu, M. A. Lovell, and B. C. Lynn, “Development of a method for quantification of acrolein-deoxyguanosine adducts in DNA using isotope dilution-capillary LC/MS/MS and its application to human brain tissue,” Analytical Chemistry, vol. 77, no. 18, pp. 5982–5989, 2005.

[103] M. D. Ledesma, P. Bonay, C. Colazo, and J. Avila, “Analysis of microtubule-associated protein tau glycation in paired helical filaments,” Journal of Biological Chemistry, vol. 269, no. 34, pp. 21614–21619, 1994.

[104] M. Takeuchi, T. Sato, J. I. Takino et al., “Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer’s disease,” Medical Hypotheses, vol. 69, no. 6, pp. 1358–1366, 2007.

[105] A. Hernanz, M. De la Fuente, M. Navarro, and A. Frank, “Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer’s disease and mild cognitive impairment patients,” Neuroimmunomodulation, vol. 14, no. 3-4, pp. 163–167, 2007.

[106] J. Wang, S. Xiong, C. Xie, W. R. Markesbery, and M. A. Lovell, “Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer’s disease,” Journal of Neurochemistry, vol. 93, no. 4, pp. 953–962, 2005.

[107] M. Corral-Debrinski, T. Horton, M. T. Lott et al., “Marked changes in mitochondrial DNA deletion levels in Alzheimer brains,” Genomics, vol. 23, no. 2, pp. 471–476, 1994.

[108] P. E. Coskun, M. F. Beal, and D. C. Wallace, “Alzheimer’s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 29, pp. 10726–10731, 2004.

[109] P. Moccucci, U. MacGarvey, and M. F. Beal, “Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease,” Annals of Neurology, vol. 36, no. 5, pp. 747–751, 1994.

[110] M. A. Lovell and W. R. Markesbery, “Oxidatively modified RNA in mild cognitive impairment,” Neurobiology of Disease, vol. 29, no. 2, pp. 169–175, 2008.

[111] A. Nunomura, S. Chiba, C. F. Lippa et al., “Neuronal RNA oxidation is a prominent feature of familial Alzheimer’s disease,” Neurobiology of Disease, vol. 17, no. 1, pp. 108–113, 2004.

[112] A. Nunomura, G. Perry, M. A. Pappolla et al., “Neuronal oxidative stress precedes amyloid-β deposition in Down syndrome,” Journal of Neuropathology & Experimental Neurology, vol. 59, no. 11, pp. 1011–1017, 2000.

[113] T. Abe, H. Tohgi, C. Isobe, T. Murata, and C. Sato, “Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer’s disease,” Journal of Neuroscience Research, vol. 70, no. 3, pp. 447–450, 2002.

[114] R. Sultana, M. Piroltti, F. Galli, and D. A. Butterfield, “Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment,” Neurochemical Research, vol. 33, no. 12, pp. 2540–2546, 2008.

[115] C. A. Massaad, “Neuronal and vascular oxidative stress in Alzheimer’s disease,” Current Neuropharmacology, vol. 9, no. 4, pp. 662–673, 2011.

[116] D. L. Marcus, C. Thomas, C. Rodriguez et al., “Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer’s disease,” Experimental Neurology, vol. 150, no. 1, pp. 40–44, 1998.
[117] M. C. Puertas, J. M. Martínez-Martos, M. P. Cobo, M. P. Carrera, M. D. Mayas, and M. J. Ramírez-Expósito, “Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia,” Experimental Gerontology, vol. 47, no. 8, pp. 625–630, 2012.

[118] M. A. Lovell, C. Xie, and W. R. Markesbery, “Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer’s disease,” Neurology, vol. 51, no. 6, pp. 1562–1566, 1998.

[119] S. L. Duffy, J. Lagopoulos, I. B. Hickie et al., “Glutathione relates to neuropsychological functioning in mild cognitive impairment,” Alzheimer’s & Dementia, vol. 10, no. 1, pp. 67–75, 2014.

[120] D. Boyd-Kimball, H. F. Poon, B. C. Lynn et al., “Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Aβ(1–42): Implications for Alzheimer’s disease,” Neurobiology of Aging, vol. 27, no. 9, pp. 1239–1249, 2006.

[121] W. O. Opip, G. Joshi, E. Head et al., “Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer’s disease,” Neurobiology of Aging, vol. 29, no. 1, pp. 51–70, 2008.

[122] R. Sultana, T. Reed, M. Perluigi, R. Coccia, W. M. Pierce, and D. A. Butterfield, “Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study,” Journal of Cellular and Molecular Medicine, vol. 11, no. 4, pp. 839–851, 2007.

[123] W. L. Niszcz, A. Gogotek, and E. Skrzylowaska, “Antioxidants and HNE in redox homeostasis,” Free Radical Biology and Medicine, vol. 111, pp. 87–101, 2017.

[124] Z. A. Wood, E. Schröder, J. Robin Harris, and L. B. Poole, “Structure, mechanism and regulation of peroxiredoxins,” Trends in Biochemical Sciences, vol. 28, no. 1, pp. 32–40, 2003.

[125] M. E. Conway and C. Lee, “The redox switch that regulates molecular chaperones,” Biochemical Concepts, vol. 6, no. 4, pp. 269–284, 2015.

[126] H. F. Poon, S. A. Farr, W. A. Banks et al., “Proteomic identification of less oxidized brain proteins in aged senescence-accelerated mice following administration of antisense oligonucleotide directed at the Aβ region of amyloid precursor protein,” Molecular Brain Research, vol. 138, no. 1, pp. 8–16, 2005.

[127] S. Ji, Y. Kim, M. Fountoulakis, N. Cairns, and G. Lubec, “Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer’s disease and Down syndrome,” Journal of Neural Transmission. Supplenta, vol. 61, pp. 223–235, 2001.

[128] F. Mangialasche, W. Xu, M. Kivipelto et al., “Tocopherols and tocotrienols plasma levels are associated with cognitive impairment,” Neurobiology of Aging, vol. 33, no. 10, pp. 2282–2290, 2012.

[129] F. J. Jiménez-Jiménez, F. de Bustos, J. A. Molina et al., “Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer’s disease,” Journal of Neural Transmission, vol. 104, no. 6-7, pp. 703–710, 1997.

[130] P. Rinaldi, M. C. Polidori, A. Metastasio et al., “Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer’s disease,” Neurobiology of Aging, vol. 24, no. 7, pp. 915–919, 2003.

[131] F. Mangialasche, M. Kivipelto, P. Memoccì et al., “High plasma levels of vitamin E forms and reduced Alzheimer’s disease risk in advanced age,” Journal of Alzheimer’s Disease, vol. 20, no. 4, pp. 1029–1037, 2010.

[132] N. T. Akbaraly, I. Hinnen-Favier, I. Carrière et al., “Plasma selenium over time and cognitive decline in the elderly,” Epidemiology, vol. 18, no. 1, pp. 52–58, 2007.

[133] U. Schweizer, F. Streckfuß, P. Pelt et al., “Heptatically derived selenoprotein P is a key factor for kidney but not for brain selenium supply,” Biochemical Journal, vol. 386, no. 2, pp. 221–226, 2005.

[134] V. Calabrese, R. Sultana, G. Scapagnini et al., “Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer’s disease,” Antioxidants & Redox Signaling, vol. 8, no. 11-12, pp. 1975–1986, 2006.

[135] S. Akterin, R. F. Cowburn, A. Miranda-Vizuete et al., “Involvement of glutaredoxin-1 and thioredoxin-1 in β-amyloid toxicity and Alzheimer’s disease,” Cell Death & Differentiation, vol. 13, no. 9, pp. 1454–1465, 2006.

[136] F. Gil-Bea, S. Akterin, T. Persson et al., “Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer’s disease brain,” EMBO Molecular Medicine, vol. 4, no. 10, pp. 1097–1111, 2012.

[137] L. M. Bekris, I. F. Mata, and C. P. Zabetian, “The genetics of Parkinson disease,” Journal of Geriatric Psychiatry and Neurology, vol. 23, no. 4, pp. 228–242, 2010.

[138] L. S. Forno, “Neuropathology of Parkinson’s Disease,” Journal of Neuropathology and Experimental Neurology, vol. 55, no. 3, pp. 259–272, 1996.

[139] M. G. Spillantini, R. A. Crowther, R. Jakes, M. Hasegawa, and M. Goedert, “α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6469–6473, 1998.

[140] A. H. V. Schapira, J. M. Cooper, D. Dexter, P. Jenner, J. B. Clark, and C. D. Marsden, “Mitochondrial complex I deficiency in Parkinson’s disease,” The Lancet, vol. 333, no. 8649, article 1269, 1989.

[141] W. D. Parker Jr and R. H. Swerdlow, “Mitochondrial dysfunction in idiopathic Parkinson disease,” The American Journal of Human Genetics, vol. 62, no. 4, pp. 758–762, 1998.

[142] M. O. Guttman, R. Sultana, A. Miranda-Vizuete et al., “Mitochondrial contribution to Parkinson’s disease pathogenesis,” Parkinson’s Disease, vol. 2011, article 159160, 7 pages, 2011.

[143] M. P. Murphy, “How mitochondria produce reactive oxygen species,” Biochemical Journal, vol. 417, no. 1, pp. 1–13, 2009.

[144] M. J. Ekstrand, M. Terzioglu, D. Galter et al., “Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 4, pp. 1325–1330, 2007.

[145] H. Elkon, J. Don, E. Melamed, I. Ziv, A. Shirvan, and D. Offen, “Mutant and wild-type α-synuclein interact with mitochondrial cytochrome C oxidase,” Journal of Molecular Neuroscience, vol. 18, no. 3, pp. 229–238, 2002.
brain,” *Journal of Biological Chemistry*, vol. 283, no. 14, pp. 9089–9100, 2008.

[147] W. D. Parker Jr, J. K. Parks, and R. H. Swerdlov, “Complex I Deficiency in Parkinson’s disease frontal cortex,” *Brain Research*, vol. 1189, pp. 215–218, 2008.

[148] E. M. Valente, P. M. Abou-Sleiman, V. Caputo et al., “Hereditary early-onset Parkinson’s disease caused by mutations in PINK1,” *Science*, vol. 304, no. 5674, pp. 1158–1160, 2004.

[149] W. C. Nichols, N. Pankratz, D. Hernandez et al., “Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease,” *The Lancet*, vol. 365, no. 9457, pp. 410–412, 2005.

[150] V. Bonifati, P. Rizzu, M. van Baren et al., “Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism,” *Science*, vol. 299, no. 5604, pp. 256–259, 2002.

[151] W. P. Gilks, P. M. Abou-Sleiman, S. Gandhi et al., “A common LRRK2 mutation in idiopathic Parkinson’s disease,” *The Lancet*, vol. 365, no. 9457, pp. 415–416, 2005.

[152] S. Gandhi, A. Wood-Kaczmar, Z. Yao et al., “PINK1-associated Parkinson’s disease is caused by neuronal vulnerability to calcium-induced cell death,” *Molecular Cell*, vol. 33, no. 5, pp. 627–638, 2009.

[153] C. Piccoli, A. Sardanelli, R. Scrima et al., “Mitochondrial respiratory dysfunction in familial parkinsonism associated with PINK1 mutation,” *Neurochemical Research*, vol. 33, no. 12, pp. 2565–2574, 2008.

[154] M. Kostic, M. H. R. Ludtmann, H. Bading et al., “PKA phosphorylation of NCLX reverses mitochondrial calcium overload and depolarization, promoting survival of PINK1-deficient dopaminergic neurons,” *Cell Reports*, vol. 13, no. 2, pp. 376–386, 2015.

[155] B. Xiao, J. Y. Goh, L. Xiao, H. Xian, K. L. Lim, and Y. C. Liou, “Reactive oxygen species trigger Parkin/PINK1 pathway-dependent mitophagy by inducing mitochondrial recruitment of Parkin,” *Journal of Biological Chemistry*, vol. 292, no. 40, pp. 16697–16708, 2017.

[156] M. Delgado-Camprubi, N. Esteras, M. P. M. Soutar, H. Plun-Favreau, and A. Y. Abramov, “Deficiency of Parkinson’s disease-related gene *Floxo* is associated with impaired mitochondrial metabolism by PARP activation,” *Cell Death and Differentiation*, vol. 24, no. 1, pp. 120–131, 2017.

[157] J. Burré, S. Vivona, J. Diao, M. Sharma, A. T. Brunger, and T. C. Südhof, “Properties of native brain α-synuclein,” *Nature*, vol. 498, no. 7453, pp. E4–E6, 2013.

[158] G. Fusco, S. W. Chen, P. T. F. Williamson et al., “Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers,” *Science*, vol. 358, no. 6369, pp. 1440–1443, 2017.

[159] E. S. Luth, I. G. Stavrovskaya, T. Bartels, B. S. Kristal, and D. J. Selkoe, “Soluble, Prefibrillar α-Synuclein Oligomers Promote Complex I-dependent, Ca2+-induced Mitochondrial Dysfunction,” *Journal of Biological Chemistry*, vol. 289, no. 31, pp. 21490–21507, 2014.

[160] K. Banerjee, M. Sinha, C. L. L. Pham et al., “α-Synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: Implications in Parkinson’s disease,” *FEBS Letters*, vol. 584, no. 8, pp. 1571–1576, 2010.

[161] P. R. Angelova, M. H. Horrocks, D. Klenerman, S. Gandhi, A. Y. Abramov, and M. S. Schepinov, “Lipid peroxidation is essential for α-synuclein-induced cell death,” *Journal of Neurochemistry*, vol. 133, no. 4, pp. 582–589, 2015.

[162] S. Mullin and A. Schapira, “α-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease,” *Molecular Neurobiology*, vol. 47, no. 2, pp. 587–597, 2013.

[163] L. J. Martin, S. Semenkov, A. Hanaford, and M. Wong, “The mitochondrial permeability transition pore regulates Parkinson’s disease development in mutant α-synuclein transgenic mice,” *Neurobiology of Aging*, vol. 35, no. 5, pp. 1132–1152, 2014.

[164] P. R. Angelova, M. H. R. Ludtmann, M. H. Horrocks et al., “Ca2+ is a key factor in α-synuclein-induced neurotoxicity,” *Journal of Cell Science*, vol. 129, no. 9, pp. 1792–1801, 2016.

[165] E. Floor and M. G. Wetzel, “Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay,” *Journal of Neurochemistry*, vol. 70, no. 1, pp. 268–275, 1998.

[166] S. R. Danielson and J. K. Andersen, “Oxidative and nitrosative protein modifications in Parkinson’s disease,” *Free Radical Biology and Medicine*, vol. 44, no. 10, pp. 1787–1794, 2008.

[167] R. Burai, N. Ait-Bouzid, A. Chiki, and H. A. Lashuel, “Elucidating the role of site-specific nitration of α-synuclein in the pathogenesis of Parkinson’s disease via protein semisynthesis and mutagenesis,” *Journal of the American Chemical Society*, vol. 137, no. 15, pp. 5041–5052, 2015.

[168] S. J. Chinta and J. K. Andersen, “Nitrosylation and nitration of mitochondrial complex I in Parkinson’s disease,” *Free Radical Research*, vol. 45, no. 1, pp. 53–58, 2011.

[169] M. F. Beal, “Oxidatively modified proteins in aging and disease,” *Free Radical Biology and Medicine*, vol. 32, no. 9, pp. 797–803, 2002.

[170] A. Yoritaka, N. Hattori, K. Uchida, M. Tanaka, E. R. Stadman, and Y. Mizuno, "Immunohistochemical detection of 4-hydroxyynonal protein adducts in Parkinson disease," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 7, pp. 2696–2701, 1996.

[171] M. L. Selley, "(E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson’s disease," *Free Radical Biology & Medicine*, vol. 25, no. 2, pp. 169–174, 1998.

[172] E. Dalfo and I. Ferrer, "Early α-synuclein lipoxidation in neocortex in Lewy body diseases," *Neurobiology of Aging*, vol. 29, no. 3, pp. 408–417, 2008.

[173] C. M. Chen, J. L. Liu, Y. R. Wu et al., “Increased oxidative damage in peripheral blood correlates with severity of Parkinson’s disease,” *Neurobiology of Disease*, vol. 33, no. 3, pp. 429–435, 2009.

[174] R. Castellani, M. A. Smith, G. L. Richey, and G. Perry, "Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease," *Brain Research*, vol. 737, no. 1-2, pp. 195–200, 1996.

[175] E. Dalfo, M. Portero-Otin, V. Ayala, A. Martinez, R. Pamplona, and I. Ferrer, "Evidence of oxidative stress in the neocortex in incidental Lewy body disease," *Journal of Neuropathology & Experimental Neurology*, vol. 64, no. 9, pp. 816–830, 2005.

[176] P. J. Thornalley, "Glycathione-dependent detoxification of α-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors," *Chemico-Biological Interactions*, vol. 111-112, pp. 137–151, 1998.
T. Abe, C. Isobe, T. Murata, C. Sato, and H. Tohgi, "Alteration of 8-hydroxyguanosine concentrations in the cerebrosplinal fluid and serum from patients with Parkinson’s disease," Neuroscience Letters, vol. 336, no. 2, pp. 105–108, 2003.

J. Zhang, G. Perry, M. A. Smith et al., "Parkinson’s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons," The American Journal of Pathology, vol. 154, no. 5, pp. 1423–1429, 1999.

R. J. Marttila, H. Lorentz, and U. K. Rinne, "Oxygen toxicity protecting enzymes in Parkinson’s disease," Journal of the Neurological Sciences, vol. 86, no. 2–3, pp. 321–331, 1988.

R. K. B. Pearce, A. Owen, S. Daniel, P. Jenner, and C. D. Marsden, "Alterations in the distribution of glutathione in the substantia nigra in Parkinson’s disease," Journal of Neural Transmission, vol. 104, no. 6–7, pp. 661–677, 1997.

M. B. Mbangata, R. V. Kartha, U. Mishra, L. D. Coles, P. J. Tuite, and J. C. Cloyd, "Oxidative stress status in patients with Parkinson’s disease on and off medication," Movement Disorders, vol. 29, p. S143, 2014.

J. Choi, H. D. Rees, L. S. Chin, and L. Li, "Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases," Journal of Biological Chemistry, vol. 280, no. 12, pp. 11648–11655, 2005.

E. Romuk, W. Szczurek, M. Olej et al., "The evaluation of the changes in enzymatic antioxidant reserves and lipid peroxidation in chosen parts of the brain in an animal model of Parkinson disease," Advances in Clinical and Experimental Medicine, vol. 26, no. 6, pp. 953–959, 2017.

M. C. Kierman, S. Vucic, B. C. Cheah et al., "Amyotrophic lateral sclerosis," The Lancet, vol. 377, no. 9769, pp. 942–955, 2011.

D. R. Rosen, T. Siddique, D. Patterson et al., "Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis," Nature, vol. 362, no. 6415, pp. 59–62, 1993.

A. C. Bowling, J. B. Schulz, R. H. Brown Jr, and M. F. Beal, "Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis," Journal of Neurochemistry, vol. 61, no. 6, pp. 2322–2325, 1993.

M. Neumann, D. M. Sampathu, L. K. Kwong et al., "Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis," Science, vol. 314, no. 5796, pp. 130–133, 2006.

J. Sreedharan, I. P. Blair, V. B. Tripathi et al., "TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis," Science, vol. 319, no. 5870, pp. 1668–1672, 2003.

V. M. van Deerlin, J. B. Leverenz, L. M. Bekris et al., "TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis," The Lancet Neurology, vol. 7, no. 5, pp. 409–416, 2008.

J. Gamez, M. Corbdera-Bellalta, G. Nogales et al., "Mutational analysis of the Cu/Zn superoxide dismutase gene in a Catalan ALS population: should all sporadic ALS cases also be screened for SOD1?" Journal of the Neurological Sciences, vol. 247, no. 1, pp. 21–28, 2006.

R. A. Saccon, R. K. A. Bunton-Stasyslyn, E. M. C. Fisher, and P. Fratta, "Is SOD1 loss of function involved in amyotrophic lateral sclerosis?" Brain, vol. 136, no. 8, pp. 2342–2358, 2013.

S. Vucic, D. Burke, and M. C. Kiernan, "Diagnosis of motor neuron disease," in The Motor Neuron Disease Handbook, M. C. Kiernan, Ed., pp. 89–115, Australasian Medical Publishing Company Limited, Sydney, 2007.

L. I. Bruijn, M. F. Beal, M. W. Becher et al., "Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 14, pp. 7606–7611, 1997.

L. I. Bruijn, M. K. Housewart, S. Kato et al., "Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1," Science, vol. 281, no. 5384, pp. 1851–1854, 1998.

F. Tafuri, D. Ronchi, F. Magri, G. P. Comi, and S. Corti, "SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis," Frontiers in Cellular Neuroscience, vol. 9, p. 333, 2015.

K. Hensley, M. Mhatre, S. Mou et al., "On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis," Antioxidants & Redox Signaling, vol. 8, no. 11–12, pp. 2075–2087, 2006.

E. L. Bastow, A. R. Peswani, D. S. J. Tarrant et al., "New links between SOD1 and metabolic dysfunction from a yeast model of Amyotrophic Lateral Sclerosis (ALS)," Journal of Cell Science, vol. 129, pp. 4118–4129, 2016.

P. M. Peixoto, H. J. Kim, B. Sider, A. Starkov, T. L. Horvath, and G. Manfredi, "UCP2 overexpression worsens mitochondrial dysfunction and accelerates disease progression in a mouse model of amyotrophic lateral sclerosis," Molecular and Cellular Neuroscience, vol. 57, pp. 104–110, 2013.

Y. Ibara, K. Nobukuni, H. Takata, and T. Hayabara, "Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation," Neurological Research, vol. 27, no. 1, pp. 105–108, 2005.

M. C. Boll, M. Alcaraz-Zubeldia, S. Montes, L. Murillo-Bonilla, and C. Rios, "Raised nitrate concentration and low SOD activity in the CSF of sporadic ALS patients," Neurochemical Research, vol. 28, no. 5, pp. 699–703, 2003.

A. Nikolić-Kokić, Z. Stević, D. Blagojević, B. Davidović, D. R. Jones, and M. B. Spasib, "Alterations in anti-oxidative defence enzymes in erythrocytes from sporadic amyotrophic lateral sclerosis (SALS) and familial ALS patients," Clinical Chemistry and Laboratory Medicine (CCLM), vol. 44, no. 5, pp. 589–593, 2006.

I. C. Shaw, P. S. Fitzmaurice, J. D. Mitchell, and P. G. Lynch, "Studies on cellular free radical protection mechanisms in the anterior horn from patients with amyotrophic lateral sclerosis," Neuromuscular Disorders, vol. 4, no. 4, pp. 391–396, 1995.

N. Shibata, "Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation," Neuropathology, vol. 21, no. 1, pp. 82–92, 2001.

P. J. Shaw, P. G. Ince, G. Falkous, and D. Mantle, "Oxidative damage to protein in sporadic motor neuron disease spinal cord," Annals of Neurology, vol. 38, no. 4, pp. 691–695, 1995.
[205] R. J. Ferrante, S. E. Browne, L. A. Shinobu et al., "Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis," Journal of Neurochemistry, vol. 69, no. 5, pp. 2064–2074, 1997.

[206] E. Onesto, C. Colombrita, V. Gumina et al., "Gene-specific mitochondria dysfunctions in human TARP6 and C9ORF72 fibroblasts," Acta Neuropathologica Communications, vol. 4, no. 1, p. 47, 2016.

[207] F. Bartolome, N. Esteras, A. Martin-Requero et al., "Pathogenic p62/SQSTM1 mutations impair energy metabolism through limitation of mitochondrial substrates," Scientific Reports, vol. 7, no. 1, article 1666, 2017.

[208] C. Capitini, S. Conti, M. Perlini et al., "TDP-43 inclusion bodies formed in bacteria are structurally amorphous, non-amylloid and inherently toxic to neuroblastoma cells," PLoS One, vol. 9, no. 1, article e86720, 2014.

[209] W. A. Pedersen, W. Fu, J. N. Keller et al., "Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients," Annals of Neurology, vol. 44, no. 5, pp. 819–824, 1998.

[210] E. P. Simpson, Y. K. Henry, J. S. Henkel, R. G. Smith, and S. H. Appel, "Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden," Neurology, vol. 62, no. 10, pp. 1758–1765, 2004.

[211] R. G. Smith, Y. K. Henry, M. P. Mattson, and S. H. Appel, "Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis," Annals of Neurology, vol. 44, no. 4, pp. 696–699, 1999.

[212] M. Perluigi, H. Fai Poon, K. Hensley et al., "Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice: A model of familial amyotrophic lateral sclerosis," Free Radical Biology and Medicine, vol. 38, no. 7, pp. 960–968, 2005.

[213] E. D. Hall, P. K. Andrus, T. J. Fleck, and M. E. Gurney, "Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS," Journal of Neuroscience Research, vol. 53, no. 1, pp. 66–77, 1998.

[214] S. Kikuchi, K. Shinpo, A. Ogata et al., "Detection of N epsilon-(carboxymethyl)lysine (CML) and non-CML advanced glycation end-products in the anterior horn of amyotrophic lateral sclerosis spinal cord," Amyotrophic Lateral Sclerosis, vol. 3, no. 2, pp. 63–68, 2002.

[215] N. Shibata, A. Hirano, T. E. Hedley-Whyte et al., "Selective formation of certain advanced glycation end products in spinal cord astrocytes of humans and mice with superoxide dismutase-1 mutation," Acta Neuropathologica, vol. 104, no. 2, pp. 171–178, 2002.

[216] J. Ilzecka, "Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis," Acta Neurologica Scandinavica, vol. 120, no. 2, pp. 119–122, 2009.

[217] K. Arai, S. Maguchi, S. Fujii, H. Ishibashi, K. Oikawa, and N. Taniguchi, "Glycation and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitro glycated sites," Journal of Biological Chemistry, vol. 262, no. 35, pp. 16969–16972, 1987.

[218] T. Murata, C. Ohtsuka, and Y. Terayama, "Increased mitochondrial oxidative damage and oxidative DNA damage contributes to the neurodegenerative process in sporadic amyotrophic lateral sclerosis," Free Radical Research, vol. 42, no. 3, pp. 221–225, 2009.

[219] S. Sussmuth, J. Brettschneider, A. Ludolph, and H. Tumani, "Biochemical markers in CSF of ALS patients," Current Medicinal Chemistry, vol. 15, no. 18, pp. 1788–1801, 2008.

[220] E. Cova, P. Bongioanni, C. Cereda et al., "Time course of oxidant markers and antioxidant defenses in subgroups of amyotrophic lateral sclerosis patients," Neurochemistry International, vol. 56, no. 5, pp. 687–693, 2010.

[221] H. Tanaka, M. Shimazawa, M. Takata et al., "ITIH4 and Gpx3 are potential biomarkers for amyotrophic lateral sclerosis," Journal of Neurology, vol. 260, no. 7, pp. 1782–1797, 2013.

[222] N. Weiduschat, X. Mao, J. Hupf et al., "Motor cortex glutathione deficit in ALS measured in vivo with the J-editing technique," Neuroscience Letters, vol. 570, pp. 102–107, 2014.

[223] H. Tohi, T. Abe, K. Yamazaki, T. Murata, E. Ishizaki, and C. Isobe, "Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis," Neuroscience Letters, vol. 260, no. 3, pp. 204–206, 1999.

[224] D. Blagojević, M. B. Spasić, and A. M. Michelson, "Glutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation," Journal of Environmental Pathology, Toxicology and Oncology, vol. 17, no. 384, pp. 325–329, 1998.

[225] M. Kuźma, Z. Jamrozik, and A. Baranczyk-Kuźma, "Activity and expression of glutathione S-transferase p in patients with amyotrophic lateral sclerosis," Clinica Chimica Acta, vol. 364, no. 1-2, pp. 217–221, 2006.

[226] A. N. Kokić, Z. Stević, S. Stojanović et al., "Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients," Redox Report, vol. 10, no. 5, pp. 265–270, 2005.

[227] P. I. Oteiza, O. D. Uchitel, F. Carrasquedo, A. L. Dubrovski, J. C. Roma, and C. G. Fraga, "Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients," Neurochemical Research, vol. 22, no. 4, pp. 535–539, 1997.

[228] L. Scott and R. J. Youle, "Mitochondrial fission and fusion," Essays In Biochemistry, vol. 47, pp. 85–98, 2010.

[229] J. Pinnell and K. Tieu, "Chapter eight - mitochondrial dynamics in neurodegenerative diseases," Advances in Neurotoxicology, vol. 1, pp. 211–246, 2017.

[230] D. H. Cho, T. Nakamura, J. Fang et al., "S-nitrosylation of Drp1 mediates β-amyloid-related mitochondrial fission and neuronal injury," Science, vol. 324, no. 5923, pp. 102–105, 2009.

[231] X. Wang, B. Su, H. G. Lee et al., "Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease," Journal of Neuroscience, vol. 29, no. 28, pp. 9090–9103, 2009.

[232] M. Manczak, M. J. Calkins, and P. H. Reddy, "Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: implications for neuronal damage," Human Molecular Genetics, vol. 20, no. 13, pp. 2495–2509, 2011.

[233] M. Manczak, R. Kandimalla, D. Fry, H. Sesaki, and P. H. Reddy, "Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease," Human Molecular Genetics, vol. 25, no. 23, pp. 5148–5166, 2016.

[234] D. Santos and S. M. Cardoso, "Mitochondrial dynamics and neuronal fate in Parkinson’s disease," Mitochondrion, vol. 12, no. 4, pp. 428–437, 2012.
[235] F. Kamp, N. Exner, A. K. Lutz et al., “Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1,” *The EMBO Journal*, vol. 29, no. 20, pp. 3571–3589, 2010.

[236] A. C. Poole, R. E. Thomas, L. A. Andrews, H. M. McBride, A. J. Whitworth, and L. J. Pallanck, “The PINK1/Parkin pathway regulates mitochondrial morphology,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 5, pp. 1638–1643, 2008.

[237] C. Vives-Bauza, C. Zhou, Y. Huang et al., “PINK1-dependent recruitment of Parkin to mitochondria in mitophagy,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 1, pp. 378–383, 2010.

[238] X. Wang, D. Winter, G. Ashrafi et al., “PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility,” *Cell*, vol. 147, no. 4, pp. 893–906, 2011.

[239] I. Irrcher, H. Aleyasin, E. L. Seifert et al., “Loss of the Parkinson’s disease-linked gene DJ-1 perturbs mitochondrial dynamics,” *Human Molecular Genetics*, vol. 19, no. 19, pp. 3734–3746, 2010.

[240] X. Wang, M. H. Yan, H. Fujioka et al., “LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLPL,” *Human Molecular Genetics*, vol. 21, no. 9, pp. 1931–1944, 2012.

[241] J. Magrane, I. Hervias, M. S. Henning, M. Damiano, H. Kawamata, and G. Manfredi, “Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities,” *Human Molecular Genetics*, vol. 18, no. 23, pp. 4552–4564, 2009.

[242] J. Gao, L. Wang, J. Liu, F. Xie, B. Su, and X. Wang, “Abnormalities of mitochondrial dynamics in neurodegenerative diseases,” *Antioxidants*, vol. 6, no. 2, p. 25, 2017.

[243] W. Wang, L. Li, W. L. Lin et al., “The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons,” *Human Molecular Genetics*, vol. 22, no. 23, pp. 4706–4719, 2013.

[244] J. Deng, M. Yang, Y. Chen et al., “FUS interacts with HSP60 to promote mitochondrial damage,” *PLOS Genetics*, vol. 11, no. 9, article e1005357, 2015.

[245] W. Song, Y. Song, B. Kincaid, B. Bossy, and E. Bossy-Wetzel, “Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1α,” *Neurobiology of Disease*, vol. 51, pp. 72–81, 2013.

[246] S. Cogliati, C. Frezza, M. E. Soriano et al., “Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency,” *Cell*, vol. 155, no. 1, pp. 160–171, 2013.

[247] M. Hamer and Y. Chida, “Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence,” *Psychological Medicine*, vol. 39, no. 1, pp. 3–11, 2009.